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Abstract
Advancement in chemistry holds a great promise in improving drug encapsula-
tion that leads to superior drug delivery efficiency and the therapeutic efficacy of
nano/micro-delivery systems. Drugs are being designed to specifically access the
infection sites via covalent conjugation to nano/micro-delivery systems. This
chapter focuses on techniques for achieving covalent encapsulation of drugs in
nano/micro-delivery systems, how conjugation is applied to selectively influence
pharmacokinetic profile, intracellular, and extracellular uptake, specific targeting to
disease sites, binding to specific receptors, and controlled/sustained release. In
addition, the effect of conjugation on drug efficacy and biosafety of the micro/
nanoparticulate drug delivery systems are discussed.
Keywords: covalent conjugation, sustained release, smart responsive,
targeted delivery
1. Introduction
For drugs to execute their effective mechanism of action, they require to reach
its targeted site of action so that they can exert their intended action [1]. While
conventional dosage formulations of drugs can achieve desired therapeutic concen-
trations, they are unable to effectively maintain the desired therapeutic concentra-
tions, conferring a limited half-life thereby leading to ineffective treatment by the
drugs [2]. Therefore, the development of novel drug delivery systems with the
ability to improve on this limitation of the conventional drug delivery systems is
needed.
Micro- and nano-carrier systems are among the approaches that have been
successfully utilized for encapsulation of various types of drugs such as peptides,
proteins, and low-molecular weight drugs [3–5]. These systems have been found to
overcome limitations of conventional dosages forms such as improving solubility
[6], bioavailability, and biodistribution of drugs [7], and targeting disease sites [8],
hence contributing to a high proportion of the active drug reaching the targeted site.
In addition, drug carrier systems protect the loaded drugs from premature degra-
dation in the biological environment, thus enhancing bioavailability and cellular
uptake. For effective delivery of drugs to occur, they have to be successfully loaded
onto drug delivery systems as payloads. Two techniques are employed in
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encapsulating drugs onto drug delivery systems. They include noncovalent physical
encapsulation and covalent linking of the drugs to drug delivery systems.
Physical encapsulation of drugs into a carrier system involves hydrophobic
interactions, electrostatic ionic interactions, and physical entrapping of drugs in the
carrier matrix [9]. While the physical encapsulation of drugs into a carrier system is
a popular technique, certain disadvantages are associated with it. For example, ionic
complexation precipitation and dose dumping may take place if the effective
attractions between the drug and the delivery system are reduced due to charge
fluctuations and short-range attractions between monomers [10]. For hydrophobic
drugs entrapped in the core of micelles, dose dumping may occur if micelles
undergo hemodilution below the critical micelle concentration [11]. Moreover,
challenges have been encountered in entrapping hydrophilic drugs in carrier sys-
tems using physical encapsulation [12]. These challenges have resulted in physical
encapsulation with low loading efficiencies. Due to this, drug delivery scientists are
resorting to covalently linking drugs to nano/micro-drug delivery system as an
alternative method to physical encapsulation. This chapter discusses the techniques
of covalent drug encapsulation, the mechanism of drug release from the covalent
linkages, efficacy, and biosafety of drugs due to covalent conjugation and how
disease site targeting via covalent conjugation is achieved.
2. Techniques of covalent drug encapsulation
Covalent drug conjugation involves attaching the drug into drug delivery sys-
tems via a physiologically labile bond [13]. A greater control over drug release is
achieved by the covalent attachment of drugs to the drug delivery systems.
Targeting and release of the drug from such systems is achieved through
hydrolysable or biodegradable linkages between the payload and the micro/
nanosystems [14]. Most commonly employed bio-hydrolysable bonds include
amide, disulfide, ester, thiol, and carbamate bonds [15]. Conjugation of the drug to
a delivery system may also include covalent linkers. The choice of a covalent linkers
used is determined by its selectivity for drug release and the environment in which
the drug should be released. Covalently conjugated drugs have exhibited the ability
to release drugs by cleaving conjugated bonds under internal or external stimuli
such as pH, redox potential, enzyme, light, and thermal energy [16].
The main advantages of covalent linking over physical encapsulation include the
enhanced residence time of the drug in the body, slow release, improved
biodistribution, and therapeutic efficacy, as well as reduced systemic toxicity
[16, 17]. Covalent drug conjugation to micro and nanosystems is achieved via
special bonds that are biodegradable or cleaved inside the body or a special envi-
ronment at disease sites. Special linker moieties and functional groups of the drug
dictate the success of conjugation on a nano/microsystem [18]. Based on the func-
tional groups available on the delivery system and the drug being conjugated,
several conjugation methods have been devised (Figure 1). The section below
discusses the techniques of drug conjugations and their application in drug delivery.
2.1 Ester-linked drug conjugates
Ester bonds are widely used in conjugating drugs to drug delivery systems [19].
The ester bond is formed when a hydroxyl group and a carboxylic acid group react.
Drugs with carboxylic groups can therefore be conjugated to hydroxyl groups of the
drug delivery system and vice versa (Figure 2). Linkers or spacers such as a succinic
anhydride may be employed to facilitate the conjugation [20]. Esterification of
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hydrophilic drugs with fatty acid is a popular technique to formulate self-
assembling particulate prodrugs. This conjugation has shown to improve cellular
uptake of hydrophilic drugs [21]. While viruses are intracellular obligate microor-
ganisms, most of the drugs employed for their treatment are DNA nucleosides
analogs which are highly hydrophilic with poor cellular uptake. Improving cellular
uptake of these drugs usually improves their activity [22]. Agarwal et al. reported
that conjugation of Emtricitabine (FTC) with myristic acid resulted to an analog
that had 35.2 times higher activity than the nonconjugated drug against multidrug-
resistant HIV viruses strain B-NNRTI and B-K65R [23]. These results indicated that
antiretroviral ester conjugation with fatty acids could generate more potent analogs
with a better resistance profile than its parent compound [24]. Similar results have
been reported via esterification of fatty acids with lamivudine (3TC) [21] and
acyclovir [25].
2.2 Amide and linked drug conjugates
Amide linkages can be used to covalently attach drugs to Nano/microcarriers
using an anchor functionalized with carboxylic acid end groups [26]. Among the
covalent linkages, amide bonds are the most widely used linkages to conjugate
drugs to drug delivery systems. The conjugation is usually catalyzed by 1-ethyl-3-
(3-(dimethylamino)propyl)carbodiimide hydrochloride (EDC) or N, N0-
dicyclohexylcarbodiimide (DCC) chemistry [27, 28]. The process involves reacting
a carboxylic group with EDC and N-hydroxysuccinimidyl (NHS) to form an acyl
amino ester that is subsequently reacted with an amine to create the amide bond.
Figure 1.
Biodegradable bonds employed in covalent drug conjugation.
Figure 2.
Synthesis of the fatty acid ester-linked Emtricitabine. Adapted from [23]. DTMTr, 4,40-dimethoxytrityl
chloride; HBTU, hexafluorophosphate benzotriazole tetramethyl uronium; DPEA, N,N-
diisopropylethylamine; DMF, dimethylformamide.
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EDC has good water solubility enabling its direct application in aqueous solutions
without the addition of any organic compounds, thus making it suitable for the
attachment of bioactive molecules to the carrier surface [29].
Several nano/micro-delivery systems with amide-linked drug conjugates have
been widely reported with a great success. Such a system was reported by
Yousefpour et al. (Figure 3) who conjugated doxorubicin and monoclonal antibody,
trastuzumab to chitosan to form nanoparticles with high conjugation capacity,
enhanced and selective uptake by human epidermal growth factor receptor 2 (Her2+)
on cancer cells compared with the nonconjugated drug. Similar conjugation was
reported by Kurtoglu et al. who conjugated Ibuprofen to PAMAM dendrimer and
mPEG via amide linkages [30]. The drug conjugates showed better results when
compared to bare drugs.
Monoclonal antibodies and derived therapeutics have also been linked with
adverse effects and toxicity. The associated toxic effects of monoclonal antibodies
Figure 3.
Schematic description of the procedures for the amide conjugation between chitosan and doxorubicin to form a
self-assembling nano-drug delivery system [29].
4
Nano- and Micro-Encapsulation - Techniques and Applications
(mAb) have limited their therapeutic application. However, antibody/drug cova-
lent (ADC) conjugation-based platform has enabled selective delivery of a potent
cytotoxic payload to target diseased cells, resulting in improved efficacy, reduced
systemic toxicity, and preferable pharmacokinetics (PK), pharmacodynamics (PD),
and biodistribution compared to traditional chemotherapy [31]. The success of such
conjugations includes FDA approved Adcetris® which is a drug conjugate of
Dolastatin 10 and monomethyl auristatin E (MMAE). The link between Dolastatin
10 and MMAE is N-terminal amine via the amide bond linked to a self-immolating
spacer, p-aminobenzyloxycarbonyl (PABC).
Apart from ADCs, amide bonds have been employed to link mAb to other drug
delivery surfaces such as liposomes. Liposomes with 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[carboxy(polyethylene glycol) (DSPE-PEG-COOH)
linked with mAb have been reported to prepare immunoliposomes. The attachment
of mAb to the liposomes was achieved via surfacedCOOH on the surface of
liposomes anddNH2 of the mAB. This conjugation enhanced significantly the
blood residence time of the mAb [32]. Another amide conjugation between targeted
ligand and liposome was reported where the peptide was covalently attached to the
Drug Drug delivery system Main findings Reference
Doxorubicin
(DOX)
Self-assembled prodrugs • Greater antitumor efficacy than free
DOX.
• High drug loading
• Sustained drug release
[34]
Adriamycin Micelles • In vivo high anticancer activity
• Low side effects
[35]
Camptothecin
and
Capecitabine
Nanofibers and spherical
nanoaggregates
• Synergism of the co-conjugated drugs
Penicillin V and
Cephradine
Aggregates • Similar activity to bare drugs
• Low on side effects
• Sustained release of the drug
[36]
DOX and
trastuzumab
Nanoparticles • Enhanced and selective uptake
• High loading capacity
• Reduction of drug side effects in Her2+
breast and ovarian cancers.
[29]
Gemcitabine Self-assembled prodrug • High loading capacity
• Increased biological half-life of the
loaded drug
• Better activity than the bare drug
[37]
Table 1.
Drug loading via amide conjugation functionalized for varied clinical and research applications.
Figure 4.
Illustration of linking drugs to the delivery system via hydrazine bond.
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carboxylic groups on the PEGylated liposomes to form a nanoparticulate system
able to target the infarcted heart. The system was effective in in vitro testing against
cardiac cells [33]. Due to their stability, the rate of hydrolysis of amide bonds is
lower when compared to ester bonds. This slower rate of hydrolysis affects the
release of drugs, thus affecting the activity of the conjugated drugs [34]. The amide
conjugation of drugs to drug delivery systems is summarized in Table 1.
2.3 Hydrazones conjugates
Hydrazones are formed by the action of hydrazine on ketones or aldehydes
functional groups [38]. Their basic structure is R1R2C]NNH2 which is formed when
oxygen in ketones and aldehydes is replaced with thedNNH2 functional group. pH-
sensitivity attributes of hydrazones bond have been used in the formation of stimuli
responsive nano/micro-drug delivery system. At a lower pH, the bond decomposes
efficiently while at basic pH, hydrazones are usually stable [39]. The instability of
hydrazone bonds in acidic mean molecules can be cleaved in acidic intracellular
environment of endosomes or lysosomes, tumor tissues, and bacterial infection sites.
Hydrazone bonds have been successfully used to covalently load drugs into delivery
systems resulting to pH-responsive nano/micro-dosage forms that can effectively
target a disease that alters physiological pH to acidic (Figure 4) [38, 40, 41].
2.4 Thioether linkage
Thioether bond is formed from the reaction between the thiol group containing
SH group and first carbon of maleimide that is attached to the drug carrier [42].
Conjugation via thioether bonds is favored technique as the bond is formed under
mild conditions, at room temperature, and in aqueous solution [26]. Thioether
linkage makes it possible to link peptides to a delivery system or drugs to peptide
(Figure 5). Several drug delivery systems have been reported to employ thioether
linkage as a means of covalently loading drug on to them. mAb trastuzumab and
nanoparticle doped with doxorubicin were successfully loaded in a drug delivery
system via thioether linkage [43]. DOX was conjugated to a drug delivery system
via thioether bond through poly(ethylene glycol) polymer having two linkers of
maleimide and n-hydroxysuccinimide (nhs). The conjugates showed better cancer
uptake when compared to free DOX. The better uptake was attributed to better
affinity of the system to the HER2 receptor of breast cancer cells. When compared
to the free drug, the conjugated delivery system had a longer blood circulation with
less toxic effects when compared to the free drug [28]. Similar results were reported
by Park et al. who formulated immunoliposomes conjugated with monoclonal anti-
bodies (mAB) [44]. Additionally, another liposomal covalent system has also been
reported by Kirpotin et al.; in the system, a free thiol group was used to conjugate
antibodies to the nanocarriers. The carrier showed increased cellular uptake
resulting in better tumor reduction [45]. Thioether linkage has also been applied
successfully on carbon nanotubes functionalized by folic acid. The system employed
in targeted delivery of DOX against cancer [46]. From literature reports, thioether-
Figure 5.
Illustration showing maleimide thiol covalent linkage to drug delivery systems.
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linked drug delivery systems can be effectively employed in targeted delivery of the
conjugated drugs.
2.5 Disulfide linkage
Two thiol groups’ conjugation results in the formation of a disulfide bond. One
group originates from a nanocarrier and the other from a ligand [47]. Disulfide drug
conjugates have shown to be stable in the extracellular environments but easily
broken down in intracellular reductive intracellular environment. There is an
increasing number of drug formulations that incorporate disulfide bonds being
reported, for nano/micro-drug delivery system. Disulfide bonds are being designed
to exploit differences in the reduction potential at disease location and the whole
body at large [18]. Formulating environmentally responsive drug delivery systems
has been made possible due to the desirable attribute of disulfide bonds. Lu et al.
using a disulfide-bridged created mesoporous silica nanoparticle covalently loaded
with folic acid (FA) and decorated bull serum albumin (BSA) for improved tissue
biocompatibility and effective dual pH/glutathione (GSH) response drug releasing
drug delivery system. Disulfides have also been employed as cleavable linkers in
drug conjugates or to formulate stimuli-responsive carriers, and this has resulted in
disulfides linker-based mAb drug covalent linkages (ADCs) in clinical trials [48].
2.6 Other covalent linkages
Other covalent linkages that include carbamate linkage, Schiff bases, and poly-
cyclic linkages have also been employed to form covalent linkages between the drug
and delivery systems. Reaction between a diene and dienophile results to cycload-
dition via the Diels-Alder chemistry which forms bicyclic compounds. This chem-
istry can be utilized to form polycyclic linkages between the drug and the delivery
system [49]. Whereas other hydrolyzable linkages include carbamate [50, 51],
oximes [52], and Schiff bases [53, 54]. These types of linkages are specifically
designed to make drug delivery systems have targeting ability due to the physio-
logical changes brought about by the diseases.
3. Self-assembly of covalent conjugated drugs
Roughly 70% of new drug discoveries have shown poor aqueous solubility, while
approximately 40% of the marketed immediate-release drugs are practically insol-
uble [55]. Additionally, the drugs that are highly soluble have been found to have
membrane penetration difficulties [56]. Covalent modification of therapeutic com-
pounds is therefore a strategy that enhances efficacies of the conjugated drugs by
solving physicochemical problems associated with the drugs [57]. When hydropho-
bic drug molecules are attached to hydrophilic material or when hydrophilic drugs
are attached to hydrophobic biomaterial or delivery systems, an amphiphilic system
is formed. The resulting amphiphilic system can self-assemble into stable core-shell
aggregates such as vesicles, classical micelles, unimolecular micelles, and nanorods
[2, 58].
When amphiphiles are dispersed in water, the hydrophilic component of the
amphiphile preferentially interacts with the aqueous phase (shell) while the hydro-
phobic portion tends to reside in the air or in the nonpolar solvent (core) in order to
form stable assemblies [59]. Self-assemblies of drug conjugates are usually governed
by forces such as hydrogen bonds, Van der Waals interactions, hydrophobic inter-
actions, and electrostatic interactions [2]. Self-assembled drug conjugates often
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result to effective therapies as they possess better physicochemical properties that
lead to enhanced drug penetration for highly hydrophilic and charged drug mole-
cules [60], enhanced solubility for highly insoluble drugs, and increased residence
time for drugs that are easily eliminated via the kidney [61]. For instance, most of
anticancer drugs are hydrophobic in nature, and therefore, to produce self-
assembled nanostructures with better therapeutic and formulation aspects, hydro-
philic molecules or polymers are usually attached to them via a degradable linker to
induce amphiphilicity and self-assembly (Figure 6) [60]. Self-assembly widely
occurs in nature and has been borrowed by science to formulate self-assembled
nano/micro-drug delivery systems with better therapeutic outcomes than original
drug molecules [62].
4. Mechanism of drug release from drug conjugates
Covalent linkages alter the absorption, distribution, metabolism, and elimina-
tion (ADME) properties of an active drug [64]. Before conjugation, it is paramount
to have a complete understanding of the physicochemical, structural relationship
activity of the drug candidates. It is also important to understand the ability of the
attached groups to cleave, leaving and exposing the functional groups responsible
for the activity of the drug [65]. Moreover, once the drug is cleaved from the
delivery system, the delivery system should be inactive and nontoxic [66]. Most of
the drawbacks from covalent linkages of drugs to the delivery systems are the
inability of the drug to cleave from the delivery system. The inability of the drug to
detach from the drug delivery system may lower the activity of the drug due to poor
bioavailability [67]. Therefore, the chosen covalent linking technique should have
the ability to easily cleave to enable the release of the drug.
Esterification is a common technique for conjugation because esterases are
widely distributed in body tissues that easily cleave the ester bonds leaving the
free drug to act. Esterase is a hydrolase enzyme that splits esters into an acid and
alcohol in a chemical reaction with water called hydrolysis [68]. The easy cleaving
of esters makes the use of ester linkages as an attractive technique. Breakage of
amide bonds is via hydrolysis of the carbon-nitrogen bond, and this results in a
carboxylic acid and either ammonia or an amine [69]. This cleavage of amides is
Figure 6.
Schematic representation of self-assembly of drug conjugates and subsequent release mechanism of the drug from
the self-assembly. Adapted with permission from [63].
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responsible for the drug release from the drug delivery systems. It is important to
note that amides are stable bonds, which do not hydrolyze at physiological pH and
body temperature.
Disulfide bonds usually exploit differences in the reduction potential at different
locations within and upon cells to release the conjugated drugs. Due to this, differ-
ent delivery platforms have been designed to achieve different targeted delivery
strategies. Redox enzymes reduce disulfide bonds on and inside the cells resulting in
drug release [18]. Other bonds like hydrazones, Schiff bases hydrolysis is catalyzed
by acid environment. In an acid environment, the bond between the drug delivery
system and the drug is broken to release the drug. Apart from direct drug linkage to
the delivery systems [70], suitable linkers that are self-immolating such as p-
aminobenzyloxycarbonyl (PABC) can also be involved in the reaction. The purpose
of the linkers is to situate the cleavable delivery system away from the drug to allow
facile release. Upon cleavage, the linkers rapidly fragment, leading to the release of
the drug in a chemically unmodified form [71, 72] (Table 2).
5. Efficacy and biosafety of drugs due to covalent conjugation
Particulate drug delivery systems have recorded significant progress in the
delivery of small molecular drugs; however, some challenges such as poor drug
loading, formulation instability, premature drug leakage, and poor blood circulation
are still encountered. This has led to the discovery of newer strategies that can be
used to overcome these challenges. Over the years, various research groups have
explored the efficacy and biosafety of drugs that were covalently conjugated to
nano/micro-delivery systems [84]. These include systems developed from poly-
mers, dendrimers, and peptides among others; usually, the drug is bond to the
biomaterial via a linker. The efficacy of drugs covalently conjugated has been
significantly improved in terms of drug loading capacity and stability amongst other
benefits. Biomaterials such as polymers that are covalently bonded to drugs have
shown to be useful drug carriers which help to hold drugs and are tunable to
increase the efficacy of the drug [85, 86].
The other advantages drug conjugation provides include increased solubility of
the drugs that are insoluble in water, thus enhancing a controlled release of the drug
as there will be increased permeability through lipophilic tissues. This will, in turn,
lead to an increased effective concentration of the drug at the targeted site [86].
Additionally, drug conjugated covalently to biomaterials are shielded from degra-
dation or deactivation as well as increases the circulation time of the drug [87]. One
or more of these advantages offered by drug conjugation has been reported by
various groups of researchers. For instance, the efficacy of different poly(ethylene
glycol) (PEG)-based anticancer drug conjugates has been extensively explored
[84, 88, 89]. The details of the importance of nano/micro-delivery systems such as
lysosomes, polymeric micelles, and polymeric nanoparticles in drug delivery
applications have also been discussed [90].
In a study [91], hydrazine-based doxorubicin-polymer conjugates were synthe-
sized into doxorubicin-loaded nanoparticles. It was reported that the bioactivity of
the drug was largely retained in vitro, and there was a tremendous reduction in
systemic toxicity of doxorubicin upon nanoparticle conjugation in vivo when com-
pared to the physical formulation of the drug. In addition, the nanoparticles
prevented the drug from disassembling upon interaction with serum proteins in the
blood [92, 93]. The in vitro study showed that the doxorubicin-nanoparticle conju-
gate accelerated the release of the drug in acidic conditions and killed the cancer
cell. In the same vein, Modarassi and colleagues investigated the drug release
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Bond Mechanism of cleavage Method of hydrolysis References
Cleavage in the body is catalyzed by esterases [73]
The bond is cleaved via hydrolysis.
Sometimes catalyzed by enzymes like esterase, hydrolase, serine
and
cysteine proteases, peptidases, antibody Fab-BL 125 and RNA
[74–80]
Cleavage is via acid-catalyzed hydrolysis [81]
Bond cleavage is achieved via acid and base catalysis and redox
potential hydrolysis catalyzed by various classes of reductases
enzyme in the presence of excess reduced glutathione (GSH)
and thioredoxin
Reductase
[18]
Drug release is via ring-opening hydrolysis and thiol exchange [82, 83]
Table 2.
Cleavage mechanism resulting in drug release of common bonds employed in covalent conjugation.
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behavior of doxorubicin that was conjugated onto the structure of nanoparticles.
The conjugation was achieved via an acid-labile hydrazone linkage, and the effect of
conjugation was compared with the nonconjugated drug [94] (Figure 7). The
results of the in vitro investigation revealed that the release of doxorubicin was
dependent on the amount of crosslinker. The higher the amount of crosslinkers, the
lower the cumulative drug release in the physically loaded drug. On the other hand,
drug conjugation showed that an increase in the amount crosslinker within the
structure led to an increased rate and amount of drug released. This implies that the
efficacy of drug conjugation with respect to drug release is superior to
nonconjugated drugs.
Another drug PEG conjugate that has shown enhanced drug efficacy is the
paclitaxel (PTX) conjugated with polyethylene glycol (PEG-B-PTX), synthesized
by Dong et al. [96]. The antitumor efficacy of the stable micelle of about 50 nm, and
13.3 wt% drug load content was investigated against human glioma and breast
cancer cells in vitro. The conjugate micelle exhibited improved antitumor effects
when compared to the clinically used taxol. This result suggests that the drug
conjugate can be a superior alternative for current clinically used PTX
nanoformulations which has limitations such as poor in vivo stability, premature
release, and little improvements in its antitumor efficacy [97, 98]. A detailed in vivo
Figure 7.
A) The hydrazone acid-labile DOX release behavior from nano/microparticles at pH 7.4. (B) The hydrazone
acid-labile DOX release behavior from nano/microparticles at pH 5.5. Sustained release slow drug release at
pH 7.4 when compared to acidic pH. Overall slower release when compared to nonconjugated DOX. Adapted
with permission from [95].
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experiment by the same research group further revealed that PEG-B-PTX showed
prolonged circulation time as well as enhanced in vivo antitumor efficacy (tumor
inhibition rate of 89.4%) with low side effects. This observation can be attributed to
the favorable pharmacokinetic profile and tumor-specific release of the drug from
the drug conjugate. This promising study has prompted other groups of researchers
to investigate the efficacy of other stimuli responsive PTX conjugates [99–103].
This same set of researchers [96] went further to demonstrate that hydrophobic
drugs can be conjugated with a short water-soluble polymer or peptide chain to
make the drug amphiphilic. It was proven that the self-assembled nanovehicles are
suitable for the delivery of the drug and even co-delivery of other drugs as reported
by other research groups [104, 105]. The effects of this approach are well-
characterized chemical structures, accurate and reproducible drug loading effi-
ciency (i.e., 100%), fixed, and high drug loading contents. Also, burst release of
drugs associated with physically drug-loaded micelles can be prevented [106].
These attributes are very important and favorable for clinical translation; therefore,
these conjugates have great potential for clinical application.
Furthermore, other studies have buttressed the potential excellent effect of drug
conjugates in combating diseases as seen in the experiment done by Li et al. [107].
Camptothecin and doxorubicin were loaded onto a polymer, and the efficiency of
the drug conjugate was explored. A synergistic drug delivery which improved the
anti-cancer efficiency of the drugs was reported. The in vitro stability study showed
that the drugs were stable with 80% drug loading after 4 weeks at a storage tem-
perature of 4°C. In addition, the in vitro studies showed an approximately 30%
increase in the cellular uptake of the conjugated drugs into the cancer cells when
compared to the free drugs. It is noteworthy that a superior anticancer efficacy was
observed in the combined drug conjugate, and the enhanced synergistic effects of
about 23.9% was attributed to the good better stability profile, internalization by
cells and pH response. Other benefits of the drug conjugate observed from this
study include suitable sizes and good water solubility. This led to the greater pene-
tration of the drugs into the solid tumors, thus improving the overall efficacy of the
drug conjugate when compared to the free drugs. From these results, it is suggested
that DOX-CPT conjugated to nano-delivery systems has the potential to provide
synergistic anticancer treatment.
The superior efficacy of drug-conjugated covalently compared to nonconjugated
drugs has also been proven by Tang and coworkers via conjugating sorafenib with
polyethylene glycol (PEG) nanoparticles. The efficacy of the drug conjugate (SFP)
was evaluated on cancer cells in an in vitro antitumor experiment [108]. The result
showed that SFP had an excellent antitumor activity due to the self-immolative
release of the intact drug inside tumor cells caused by the GSH-responsive disulfide
linker thus suggests that SFP may be a potential candidate for cancer treatment.
Additionally, it was reported that the covalent drug conjugation prevented drug
leakage and improved drug stability. SFP is therefore a promising nano/micro-
carrier for safe drug delivery which may pave room for new opportunities to
explore other drug conjugates. Among other studies, Daniel et al. have reported that
drug conjugates especially polymer conjugates are potentially suitable for the deliv-
ery of antiviral drugs [109, 110]. A typical example is the synthesis of poly(lactide-
co-glycolide) nanoparticles loaded with a combination of reverse transcriptase and
protease inhibitors. Such drug conjugates have been reported to be effective in
preventing the replication process of HIV replication [111, 112]. This implies that
drug conjugates are a promising approach in improving the therapeutic efficacy of
therapeutic agents, and this may encourage their clinical translation.
12
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Irrespective of the excellent efficacy of any drug conjugates, before their appli-
cation, it is very important that the biosafety is proven and confirmed to be harm-
less to the human system. Hence, it has become necessary that developed drug
conjugates are evaluated for its biosafety. This has led to the investigation of the
toxicity of different drug conjugates by various researchers. For instance, an in vitro
cytotoxicity study was carried out by Tang and fellow workers, and the cytotoxicity
of the drug-conjugate was assessed using the MTT assay method [108]. The study
investigated the cytotoxicity effect of sorafenib-polyethylene glycol (PEG)
nanoparticles conjugate (SFP) on Hela and HepG2, respectively, after incubation
for 48 h at 37°C. The result showed a dose-dependent cytotoxic effect of free
sorafenib (SF) and SFP on both cell lines, and no significant difference in cytotox-
icity was observed for SF and SFP on both cell lines. Nonetheless, a higher cytotox-
icity of SFP was displayed between the concentration ranges of 5–15 μM when
compared to free SF. The higher in vitro cytotoxicity of SFP observed at those
concentrations may be due to the increased intracellular localization of SFP
nanoparticles. This suggests that the conjugation of sorafenib with a polyethylene
glycol (PEG) nanoparticle does not have a negative influence on the toxicity as seen
in the favorably cytotoxic effect on both cell lines. Also, the ability of SFP to serve as
a biosafe anticancer therapeutic agent was further confirmed in the
hemocompatibility and histological safety results. These nontoxic properties of the
drug conjugate can be attributed to the outer PEG shell of SFP.
Furthermore, drawbacks such as dose-dependent toxicity have been reported
with drug conjugates; therefore, in an attempt to minimize toxicity, Li et al. have
evaluated the effect of combining drugs onto a nano-drug delivery system on
toxicity [107]. The cell cytotoxicity of the DOX and CPT conjugate versus the free
drugs showed enhanced uptake in the cancer cells but reduced in the normal cells
exposed to the drug-conjugate. Additionally, it was reported that the side effects of
the drugs (doxorubicin and camptothecin) employed in the study decreased by
reducing the dosage of the drugs. The toxic side effects of the drugs were alleviated,
and it was also observed that the multidrug resistance (MDR) was reversed. This
may be attributed to the synergistic effects of multiple therapeutic agents
[113, 114]. Remarkably, to assess the general biosafety of drug conjugates, Ibrahim
et al. have gone further into in vivo investigation of the drug conjugates developed
by their group [115]. The organs of mice exposed to these drug conjugates for
21 days were sliced and analyzed histologically. It was noted that exposure to the
tissues (heart, liver, spleen, lung, and kidney) did not result in any tissue damage;
hence, the biocompatibility of the formulations was confirmed. Other studies that
reported little or no toxic side effects of drug conjugates are Dong and Lu with their
co-workers, respectively [96, 116].
In the cytotoxicity study carried by Lu et al., pullulan which is a natural bio-
compatible polysaccharide was used to synthesize a novel pH-sensitive nanoparticle
drug delivery system for the delivery of doxorubicin (DOX) [116]. The chemical
structure of the pullulan/DOX conjugate nanoparticles was assessed using FTIR and
1H NMR and further investigated for in vitro drug release and cytotoxicity activi-
ties, respectively. The result of the release behavior in vitro showed that a faster
release of DOX was released from the drug delivery at pH 5.0 than at pH 7.4. It was
observed that lower concentrations of the drug (DOX) were more cytotoxic to 4 T1
cells than pullulan/DOX conjugate nanoparticles at a concentration range of 0.01–
5 mg/l. This may be due to the ability of free DOX to readily transport into the cells
via passive diffusion [117]. On the other hand, low cytotoxicity was reported for
DOX released from the nanoparticle. This may be due to a time-consuming DOX
release from nanoparticles and delayed nuclear uptake in 4 T1 cells [118]. Lin et al.
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improved biosafety of profile of cisplatin by converting it a prodrug. The prodrug
has higher survival rate of the zebrafish embryos [119] (Figure 8).
From the observations made in these studies, it is clear that drug conjugation
impacts positively on the efficacy of the drug as well as its biosafety/toxicity. The
biosafety concerns are greatly eliminated or minimized by conjugating drugs to
biomaterials. Some unwanted side effects, toxicity, and organ damage associated
with the fluctuations that arise from periodic drug administration can be avoided by
Figure 8.
Biosafety evaluation of free cisplatin and prodrug cisplatin using zebrafish embryos. Survival rates of embryos in
the presence of (a) the bare drug and (b) prodrug. Hatching rates of zebrafish embryos after the exposure to (c)
the bare drug (d) prodrug. (e) Pictogram representation the embryos with treatment of prodrug at different
concentrations over a period of 96 hours.
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drug conjugation [120]. Surprisingly, it appears that a substantial number of anti-
cancer drugs and polymers are the most explored in covalent drug conjugation
compared to other therapeutic drugs and biomaterials. This may be because
polymer-drug conjugates provide more advantages in enhancing stability, increas-
ing water solubility, and prolonging blood circulation [121–123]. Despite these
advantages, certain drawbacks such as difficulty to accurately control the reaction
site and the degree of conjugation have been associated with polymer-drug conju-
gates. Thus, the ability to reduce the heterogeneity and batch-to-batch difference of
the product remains a challenge [86, 124]. It is therefore suggested that more
studies to be done to overcome these challenges; this will provide more information
on the efficacy and biosafety of drug conjugates (Figure 9). Furthermore, reports
from these studies revealed that the efficacy and biosafety of the drugs conjugated
onto various nano/micro-delivery systems were significantly enhanced when com-
pared to the free drugs. Other nano/micro-delivery systems and drugs that have
been explored are summarized in Table 3. The table highlights the key findings of
various nano/micro-delivery systems that have been reported by different groups of
scientists.
Figure 9.
Key benefits derived from drug conjugation.
Nano/micro-delivery
system
Drug Target Outcome References
Polyglutamic acid Paclitaxel Nonsmall-
cell lung
cancer
(NSCLC)
Paclitaxel poliglumex
reduced the systemic
exposure to peak
concentrations of free
paclitaxel. In addition, the
drug-conjugate produced
similar survival to docetaxel
as second-line treatment in
NSCLC with less febrile
neutropenia and alopecia
and greater ease of
administration.
[136]
PEG-b-PCC poly(2-
methyl-2-carboxyl-
propylene carbonate)
polymer
Gemcitabine and
dodecanol
Pancreatic
cancer
In vivo studies showed a
significant increase in the
effectiveness of drug-
conjugate when compared to
the free drug.
[137]
Hyaluronic acid (HA) Cisplatin H1299, H358
cell lines and
mice
HA-cisplatin conjugate
bounded to CD44 expressing
cancer cell lines (H1299 and
H358). The drug-conjugate
was more effective in killing
lung tumors in mice when
compared to the free drug
[138]
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Nano/micro-delivery
system
Drug Target Outcome References
Poly(styrene-comaleic
acid
Neocarzinostatin Liver and
renal cancer
Arterial infusion therapy
with poly(styrene-co-maleic
acid)-conjugated
neocarzinostatin SMANCS/
Lpd showed to be effective
for large renal cell carcinoma
[139]
Poly(methyl
methacrylate) (PMMA)
polymer
Gemcitabine A549 cell-
derived
xenograft
murine
model
In vivo experiment showed
that the Gem-conjugates
reduced tumor growth by
68% with little toxicity while
free Gem had no effect but
significant toxicity.
[140]
PEG Interferon α2a/b Hepatitis B The HBsAg clearance rate
was significantly greater in
the group treated with drug-
conjugate compared to the
standard therapy group at 24
and 48 weeks post-treatment
(33.3% vs. 10.5% and 35.7%
vs. 10.5%, respectively;
P<0.05 for both).
[141]
Glycol chitosan (GC) Heparin Lungs, mice GC-heparin conjugates were
safe in the lungs and
revealed comparable blood
coagulation times compared
to free heparin
[142]
Chimeric peptides
(CPs)
Doxorubicin 4 T1 and
Lewis lung
cancers
Increased intratumoral
accumulation of the
conjugate with a curative
effect in 60% of the treated
mice was observed
[143]
Poly(amidoamine)
(PAMAM)
Doxorubicin Mice bearing
melanoma
(B16-F10)
lung
metastases
Prolonged lung retention of
drug-dendrimer conjugate
compared to free drug.
Improved chemotherapeutic
activity on the lung of mice
compared to the free drug
[144]
Poly(2-ethyl-2-
oxazoline)
Rotigotine Parkinson
disease
POZ-conjugated rotigotine
showed the potential to be
viable for subcutaneous
treatment for PD patients.
[145]
Glycol chitosan Doxorubicin Drug-conjugate accumulated
within tumors via the EPR
effect, and a significant
antitumor activity was
observed compared to free
doxorubicin
[146]
Carbopol®(CP) Calcitonin A549 cells;
rats
Drug-conjugate showed no
signs of toxicity and
maximally lowered blood
calcium levels when
compared to calcitonin alone
[147]
Carboxymethylcellulose Docetaxel EMT-6
breast cancer
Biodistribution studies
showed a 5.5-fold greater
tumor accumulation of drug-
[148]
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6. Effect of covalent drugs conjugation on the pharmacokinetic profile
of the drug
The pharmacokinetic profile of drugs is a very crucial aspect that is considered for
clinical application. It is interesting to observe that the pharmacokinetic profile of
drugs is becoming better due to covalent drug conjugation as demonstrated by drugs
encapsulated to nano/micro-delivery systems. The conjugation of drugs to biomate-
rials has opened opportunities to alter the pharmacokinetics and biodistribution of
the drugs within the human body [120]. The alteration of the pharmacokinetics of the
drug offers advantages such as prevention of the rapid clearance or metabolism of the
drug. In addition, the drugs are carried to the targeted site of pharmacological action.
Drug conjugation to nano/micro-delivery system has shown to be a powerful tech-
nique that can alter the pharmacokinetic profile of the drug, thus minimize the side
effect of various anticancer drugs such as doxorubicin.
One of the studies that reported the enhanced pharmacokinetic properties of
anticancer drug encapsulated to a nanoparticle is that conducted by Vandriess et al.
[91]. It was observed that the nanoparticles containing the drug enhanced the drug
accumulation and a subsequent reduction of tumor growth in an in vivo zebrafish
model. Also, another study has revealed that self-assembling drug polymer conju-
gates which allows a covalent attachment of the drug to the hydrophilic part of the
polymer can improve the pharmacokinetic profile of drugs. Thus, covalently
Nano/micro-delivery
system
Drug Target Outcome References
conjugate compared to the
clinically administered DTX
formulation (Taxotere).
Drug-conjugate also showed
a two-fold improvement in
anticancer activity in a
murine EMT-6 breast cancer
model compared to
Taxotere.
Hyaluronic acid, Paclitaxel (PTX) Breast cancer PTX conjugate showed more
enhanced in vivo tumor
inhibition effects compared
to free PTX.
[149, 150]
PEG-b-poly(glutamic
acid) micelle
Oxaliplatin Mouse model
of human
carcinoma
cell line KB.
The antitumor efficacy of
drug-conjugate was superior
to that of oxaliplatin. Also,
the animals did not develop
acute cold hypersensitivity,
which is frequently
experienced by patients after
oxaliplatin administration.
[151]
PEG Alendronate Lung
mucosal
The drug-conjugate
suppressed lung mucosal
toxicity after pulmonary
delivery, whereas the
administration of the free
drug-induced significant
toxicity.
[152]
Table 3.
Key observations made from other drug conjugates.
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conjugating drugs to delivery systems improves pharmacokinetic profiles and
physicochemical problems associated with certain free drugs [125]. Benefits from
covalent conjugations include prevention of rapid renal clearance, and improved
drug solubility is derived. It is however important to note that the attachment of a
large number of hydrophobic drugs to nanocarriers such as polymers may result in
unwanted aggregation and precipitation in some cases [126].
In one of the first studies, research groups such as Kataoka et al. took advantage
of the self-aggregation behavior of drug conjugates to develop a micelle forming
drug conjugate [127]. In their study, doxorubicin (DOX) was conjugated to a poly
(ethylene glycol)-poly(aspartic acid) block copolymer (PEG-b-P(Asp(DOX)), and
the pharmacokinetic profile was investigated. It was observed that there was no
interaction between the drug and serum albumin, which is known to bind to the
DOX. The inability for the drug and the serum albumin to interact indicates the
shielding ability of the nano/micro-delivery system which led to a good
biodistribution and therapeutic effect of the drug. Other subsequent studies by the
same research group aimed to improve the synthesis [128] and pharmacokinetics
profile [129, 130] of the same drug-polymer conjugate. The drug conjugate was
designed via an amide bond which can only cleave to release the drug by enzymatic
action. The results showed that the drug conjugate had a better pharmacokinetic
profile when compared to the free DOX. Interestingly, the conjugate was better
tolerated despite needing a higher dose to achieve the same effect as free DOX.
Figure 10.
Control (phosphate buffer system), camptothecin (CPT), and micellar nanoparticles drug conjugates (PC-NPs
and PCI-NPs) effectiveness on 22 tumor-bearing BALB/c mice after (A) graphs displaying tumor growth
inhibition (B) effect on tumor shrinkage after treatment with PBS, CPT, PC-NPs, and PCI-NPs at 21st day
post-treatment of the mice (C) micro-photographs of the harvested tumors. (D) Changes in the bodyweight of
the mice during treatment. (E) H&E histological images of different treatment groups. Adapted with permission
from [115].
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Similarly, more recent studies have further shown that covalent linked prodrugs
improve the pharmacokinetics and biodistribution of the conjugated drug as
reported by Ibrahim and co-workers. H22 tumor model was induced in BALB/c
[115]; the mice were exposed to conjugated drug delivery system and free-drug
camptothecin (CPT), respectively. From the results, conjugates had a significantly
had better pharmacokinetic profile than the free drug, this also led to increased
accumulation of the drug within the tumor tissues and consequently better activity.
This observation can be associated with the enhanced permeability and retention
(EPR) effect provided by the nano/micro-delivery system. An additional observa-
tion which is the biodistribution effect of the drug conjugate is seen in the out-
standing inhibition of tumor growth that resulted in better tumor shrinkage when
compared to other groups (Figure 10). After 21 days of treatment, the drug-
conjugated delivery system had a 33-fold less of tumor when compared to the
untreated group. It is presumed that the acidity of the tumor contributed to the
enhanced anticancer effect by the drug conjugated delivery system after cellular
uptake of the nanoparticles, and the drug was released in the cytosol. This might
have been the reason for the overall better activity of the conjugated drugs com-
pared to the free drug. This was attributed to the extended blood circulation and
better accumulation of conjugates in tumor compared to free CPT. Overall, these
studies suggest that by covalently conjugating drugs into nano/micro-delivery
systems, and a more enhanced pharmacokinetic profile of drugs can be obtained.
7. Disease site targeting via covalent conjugation
The delivery of drugs to sites of target, where the action of the drug is required,
is challenging due to various physicochemical, biopharmaceutical, and pharmaco-
kinetic barriers the drug may face [126]. In order to address these issues, new
approaches such as drug covalently conjugated to nano/micro-delivery systems are
being explored which alters the pharmacokinetic properties of the drug. This is
achieved by using drug various carriers such as polymers [131, 132] liposomes [133],
and dendrimers [134] that are capable of protecting the payload drug and delivering
it to the disease site. The nano/micro-delivery systems help in accumulating the
drug in the tumor site and prolong the circulation time [91]. This consequently
leads to a successful drug target to the specific disease site. Drug conjugates have
been widely utilized in the field of cancer therapy because they can passively target
cancer disease sites by permeating and retain the drug via tumor’s leaky vasculature
[135]. Apart from the ability of the nano/micro-delivery system to protect the drug
from degradative processes such as hydrolysis and metabolism before arriving at
the target site, the drug is able to accumulate in the targeted site. This ability is a
major advantage that drug conjugates proffers, which enhances their antitumor
activity. Additionally, the ability of the drug conjugate to disassemble provides the
opportunity to tune the drug release rate at the target site. More so, the tuning or
decorating the surface of the nanostructure (drug conjugate) can lead to enhanced
tumor targeting compared to drugs in their free form [126]. The enhanced drug
efficacy reported in the studies discussed earlier is closely associated with the ability
of the drug conjugate to target the specific disease site.
The advantages of covalently conjugating drugs to nano/micro-delivery systems
to target disease sites or site of infections has shown effective by results obtained by
various researchers who employed different therapeutic agents and nano/micro-
delivery systems in targeting specific disease sites as highlighted in Table 3. In all
the reported study on drug targeting using drug conjugates, a superior targeting of
drugs to disease site was displayed by the drug encapsulated to nano/micro-delivery
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systems via covalent conjugation compared to the free drug. Thus, it implies that
covalently conjugated drug-nano/micro-delivery systems have the potential to spe-
cifically target disease site; hence, it can be used to treat and manage diseases that
appear to be challenging to combat.
8. Conclusions and future perspectives
Drug encapsulation to nano/micro-delivery systems is a field in nanotechnology
that has been growing substantially over the last two decades. Specifically, the
covalent conjugation of drugs to different nano/micro-delivery systems is one of the
drug encapsulation techniques that is gaining increasing attention. Various
nanocarriers are currently developed and explored for the delivery of a wide range
of therapeutic agents such as peptides, small molecules, and drugs. The several
advantages offered by covalently conjugating this therapeutics into nanocarriers
have made them gradually more attractive. These advantages include prolonged
circulation, controlled release, improved solubility, reduced immunogenicity, spe-
cific site targeting, enhanced biosafety pharmacokinetics and biodistribution, and
combination or concurrent integration of therapeutics in a single carrier. Due to the
great strides that have been achieved in the development of effective drug delivery
systems via covalent conjugation and their immense potential, some of these con-
jugates are gaining entrance into the market. Therefore, it is anticipated that cova-
lent conjugation will continue to advance to facilitate the translation of current
research findings into innovative treatments for a broad range of diseases. How-
ever, it is still very important to have a comprehensive knowledge of the ideal
physiochemical properties, safety, drug release rates and efficacy, pharmacokinetic
behavior, and clearance kinetics of these systems before preclinical development
and clinical translation. Hence, more efforts and focused research are required to
address the knowledge gaps and provide desired information that can accelerate
their clinical translation and application in diverse fields of biomedicine. The com-
putational and theoretical modeling approach can also be employed to correlate and
answer certain outcomes by providing concrete design parameters.
20
Nano- and Micro-Encapsulation - Techniques and Applications
Author details
Victoria Fasiku1, Edith K. Amuhaya2*, Kingo M. Rajab3 and Calvin A. Omolo2*
1 Discipline of Pharmaceutical Sciences, College of Health Sciences, University of
KwaZulu-Natal, Durban, South Africa
2 Department of Pharmaceutics, School of Pharmacy and Health Sciences,
United States International University-Africa, Nairobi, Kenya
3 Department of Biomedical Sciences, College of Health Sciences, University of
Dodoma, Dodoma, Tanzania
*Address all correspondence to: eamuhaya@usiu.ac.ke; comolo@usiu.ac.ke
© 2020TheAuthor(s). Licensee IntechOpen. This chapter is distributed under the terms
of theCreativeCommonsAttribution License (http://creativecommons.org/licenses/
by/3.0),which permits unrestricted use, distribution, and reproduction in anymedium,
provided the original work is properly cited.
21
Nano/Microparticles Encapsulation Via Covalent Drug Conjugation
DOI: http://dx.doi.org/10.5772/intechopen.93364
References
[1] Petros RA, DeSimone JM. Strategies
in the design of nanoparticles for
therapeutic applications. Nature
Reviews Drug Discovery. 2010;9:
615-627
[2]Omolo CA, Kalhapure RS,
Agrawal N, Jadhav M, Rambharose S,
Mocktar C, et al. A hybrid of mPEG-b-
PCL and G1-PEA dendrimer for
enhancing delivery of antibiotics.
Journal of Controlled Release. 2018;290:
112-128
[3]Hassan D, Omolo CA, Gannimani R,
Waddad AY, Mocktar C, Rambharose S,
et al. Delivery of novel vancomycin
nanoplexes for combating methicillin
resistant Staphylococcus aureus
(MRSA) infections. International
Journal of Pharmaceutics. 2019;558:
143-156
[4]Omolo CA, Megrab NA,
Kalhapure RS, Agrawal N, Jadhav M,
Mocktar C, et al. Liposomes with pH
responsive ‘on and off’ switches for
targeted and intracellular delivery of
antibiotics. Journal of Liposome
Research. 2019:1-19
[5]Ulbrich K, Hola K, Subr V,
Bakandritsos A, Tucek J, Zboril R.
Targeted drug delivery with polymers
and magnetic nanoparticles: Covalent
and noncovalent approaches, release
control, and clinical studies. Chemical
Reviews. 2016;116:5338-5431
[6]Omolo CA, Kalhapure RS,
Agrawal N, Rambharose S, Mocktar C,
Govender T. Formulation and molecular
dynamics simulations of a fusidic acid
nanosuspension for simultaneously
enhancing solubility and antibacterial
activity. Molecular Pharmaceutics.
2018;15:3512-3526
[7] das Neves J, Araújo F, Andrade F,
Amiji M, Bahia MF, Sarmento B.
Biodistribution and pharmacokinetics of
dapivirine-loaded nanoparticles after
vaginal delivery in mice. Pharmaceutical
Research. 2014;31:1834-1845
[8]Maji R, Omolo CA, Agrawal N,
Maduray K, Hassan D, Mokhtar C, et al.
pH-responsive lipid–dendrimer hybrid
nanoparticles: An approach to target and
eliminate intracellular pathogens.
Molecular Pharmaceutics. 2019;16:
4594-4609
[9] Lee JH, Yeo Y. Controlled drug
release from pharmaceutical
nanocarriers. Chemical Engineering
Science. 2015;125:75-84
[10]Weinbreck F, de Vries R,
Schrooyen P, de Kruif CG. Complex
coacervation of whey proteins and gum
arabic. Biomacromolecules. 2003;4:
293-303
[11] Chiappetta DA, Sosnik A. Poly
(ethylene oxide)–poly (propylene
oxide) block copolymer micelles as drug
delivery agents: Improved
hydrosolubility, stability and
bioavailability of drugs. European
Journal of Pharmaceutics and
Biopharmaceutics. 2007;66:303-317
[12] Vrignaud S, Benoit J-P, Saulnier P.
Strategies for the nanoencapsulation of
hydrophilic molecules in polymer-based
nanoparticles. Biomaterials. 2011;32:
8593-8604
[13] Elvira C, Gallardo A, San Roman J,
Cifuentes A. Covalent polymer-drug
conjugates. Molecules. 2005;10:114-125
[14]D’Emanuele A, Attwood D.
Dendrimer-drug interactions. Advanced
Drug Delivery Reviews. 2005;57:
2147-2162
[15] Kim S-W, Lee YK, Kim S-H, Park J-Y,
Lee DU, Hong JH, et al. Covalent, non-
covalent, encapsulated nanodrug regulate
the fate of intra- and extracellular
22
Nano- and Micro-Encapsulation - Techniques and Applications
trafficking : Impact on cancer and normal
cells. Scientific Reports. 2017;7:1-17.
Article id: 6454
[16] Kaminskas LM, McLeod VM,
Porter CJH, Boyd BJ. Association of
chemotherapeutic drugs with dendrimer
nanocarriers: An assessment of the
merits of covalent conjugation compared
to noncovalent encapsulation. Molecular
Pharmaceutics. 2012;9:355-373
[17] Kaminskas LM, Boyd BJ, Karellas P,
Krippner GY, Lessene R, Kelly B, et al.
The impact of molecular weight and
PEG chain length on the systemic
pharmacokinetics of pegylated poly L-
lysine dendrimers. Molecular
Pharmaceutics. 2008;5:449-463
[18] Saito G, Swanson JA, Lee KD. Drug
delivery strategy utilizing conjugation
via reversible disulfide linkages: Role
and site of cellular reducing activities.
Advanced Drug Delivery Reviews.
2003;55:199-215
[19] Lele B, Hoffman A. Mucoadhesive
drug carriers based on complexes of
poly (acrylic acid) and PEGylated drugs
having hydrolysable PEG–anhydride–
drug linkages. Journal of Controlled
Release. 2000;69:237-248
[20]Khandare J, Minko T. Polymer–drug
conjugates: Progress in polymeric
prodrugs. Progress in Polymer Science.
2006;31:359-397
[21] Agarwal HK, Chhikara BS,
Hanley MJ, Ye G, Doncel GF, Parang K.
Synthesis and biological evaluation of
fatty acyl ester derivatives of ()-20,30-
dideoxy-30-thiacytidine. Journal of
Medicinal Chemistry. 2012;55:
4861-4871
[22]Debart F, Abes S, Deglane G,
Moulton HM, Clair P, Gait MJ, et al.
Chemical modifications to improve the
cellular uptake of oligonucleotides.
Current Topics in Medicinal Chemistry.
2007;7:727-737
[23] Agarwal HK, Chhikara BS,
Bhavaraju S, Mandal D, Doncel GF,
Parang K. Emtricitabine prodrugs with
improved anti-HIV activity and cellular
uptake. Molecular Pharmaceutics. 2013;
10:467-476
[24] Takalani F, Kumar P, Kondiah PP,
Choonara YE, Pillay V. Lipid–drug
conjugates and associated carrier
strategies for enhanced antiretroviral
drug delivery. Pharmaceutical
Development and Technology. 2020;25:
267-280
[25] Adhikari P, Pal P, Das AK, Ray S,
Bhattacharjee A, Mazumder B. Nano
lipid-drug conjugate: An integrated
review. International Journal of
Pharmaceutics. 2017;529:629-641
[26]Nobs L, Buchegger F, Gurny R,
Allémann E. Current methods for
attaching targeting ligands to liposomes
and nanoparticles. Journal of
Pharmaceutical Sciences. 2004;93:
1980-1992
[27]Hoare DG, Koshland DE. A method
for the quantitative modification and
estimation of carboxylic acid groups in
proteins. Journal of Biological
Chemistry. 1967;242:2447-2453
[28]Werengowska-Ciećwierz K,
Wis̈niewski M, Terzyk AP,
Furmaniak S. The chemistry of
bioconjugation in nanoparticles-based
drug delivery system. Advances in
Condensed Matter Physics. 2015;2015
(2015):198175-198202
[29] Yousefpour P, Atyabi F,
Vasheghani-Farahani E, Movahedi A-
AM, Dinarvand R. Targeted delivery of
doxorubicin-utilizing chitosan
nanoparticles surface-functionalized
with anti-Her2 trastuzumab.
International Journal of Nanomedicine.
2011;6:1977-1990
[30]Kurtoglu YE, Mishra MK, Kannan S,
Kannan RM. Drug release characteristics
23
Nano/Microparticles Encapsulation Via Covalent Drug Conjugation
DOI: http://dx.doi.org/10.5772/intechopen.93364
of PAMAM dendrimer–drug conjugates
with different linkers. International
Journal of Pharmaceutics. 2010;384:
189-194
[31] Kizhedath A,Wilkinson S, Glassey J.
Applicability of predictive toxicology
methods formonoclonal antibody
therapeutics: Status quo and scope.
Archives ofToxicology. 2017;91:1595-1612
[32]Maruyama K, Takizawa T, Yuda T,
Kennel SJ, Huang L, Iwatsuru M.
Targetability of novel
immunoliposomes modified with
amphipathic poly(ethylene glycol)s
conjugated at their distal terminals to
monoclonal antibodies. Biochimica et
Biophysica Acta. 1995;1234:74-80
[33]Dvir T, Bauer M, Schroeder A,
Tsui JH, Anderson DG, Langer R, et al.
Nanoparticles targeting the infarcted
heart. Nano Letters. 2011;11:4411-4414
[34]Duhem N, Danhier F, Pourcelle V,
Schumers J-M, Bertrand O, LeDuff CS,
et al. Self-assembling doxorubicin–
tocopherol succinate prodrug as a new
drug delivery system: Synthesis,
characterization, and in vitro and
in vivo anticancer activity. Bioconjugate
Chemistry. 2014;25:72-81
[35] Yokoyama M, Miyauchi M,
Yamada N, Okano T, Sakurai Y,
Kataoka K, et al. Characterization and
anticancer activity of the micelle-forming
polymeric anticancer drug adriamycin-
conjugated poly(ethylene glycol)-poly
(aspartic acid) block copolymer. Cancer
Research. 1990;50:1693
[36]Nathan A, Zalipsky S, Ertel SI,
Agathos SN, Yarmush ML, Kohn J.
Copolymers of lysine and polyethylene
glycol: A new family of functionalized
drug carriers. Bioconjugate Chemistry.
1993;4:54-62
[37] Gupta A, Asthana S, Konwar R,
Chourasia M. An insight into potential
of nanoparticles-assisted chemotherapy
of cancer using gemcitabine and its fatty
acid prodrug: A comparative study.
Journal of Biomedical Nanotechnology.
2013;9:915-925
[38] Sonawane SJ, Kalhapure RS,
Govender T. Hydrazone linkages in pH
responsive drug delivery systems.
European Journal of Pharmaceutical
Sciences. 2017;99:45-65
[39]Matson JB, Stupp SI. Drug release
from hydrazone-containing peptide
amphiphiles. Chemical
Communications. 2011;47:7962-7964
[40] Vijayakameswara Rao N, Mane S,
Kishore A, Sarma JD, Shunmugam R,
et al. Norbornene derived doxorubicin
copolymers as drug carriers with pH
responsive hydrazone linker.
Biomacromolecules. 2012;13:221-230
[41]Gu Y-J, Cheng J, Jin J, Cheng SH,
Wong W-T. Development and
evaluation of pH-responsive single-
walled carbon nanotube-doxorubicin
complexes in cancer cells. International
Journal of Nanomedicine. 2011;6:2889
[42] Christie RJ, Fleming R, Bezabeh B,
Woods R, Mao S, Harper J, et al.
Stabilization of cysteine-linked antibody
drug conjugates with N-aryl
maleimides. Journal of Controlled
Release. 2015;220:660-670
[43] Anhorn MG, Wagner S, Kreuter J,
Langer K, von Briesen H. Specific
targeting of HER2 overexpressing breast
cancer cells with doxorubicin-loaded
trastuzumab-modified human serum
albumin nanoparticles. Bioconjugate
Chemistry. 2008;19(12):2321-2331
[44] Park JW, Hong K, Carter P,
Asgari H, Guo LY, Keller GA, et al.
Development of anti-p185(HER2)
immunoliposomes for cancer therapy.
Proceedings of the National Academy of
Sciences of the United States of
America. 1995;92:1327-1331
24
Nano- and Micro-Encapsulation - Techniques and Applications
[45] Kirpotin D, Park JW, Hong K,
Zalipsky S, Li WL, Carter P, et al.
Sterically stabilized anti-HER2
immunoliposomes: Design and targeting
to human breast cancer cells in vitro.
Biochemistry. 1997;36:66-75
[46] Lu YJ, Wei KC, Ma CCM, Yang SY,
Chen JP. Dual targeted delivery of
doxorubicin to cancer cells using folate-
conjugated magnetic multi-walled
carbon nanotubes. Colloids and Surfaces
B: Biointerfaces. 2012;89:1-9
[47]West K, Otto S. Reversible covalent
chemistry in drug delivery. Current
Drug Discovery Technologies. 2005;2:
123-160
[48] Chari RV. Expanding the Reach of
Antibody-Drug Conjugates. ACS
Medicinal Chemistry Letters. 2016:7
(11):974-976
[49] Rau H, Baron J, Hersel U, Krusch M.
Prodrugs Containing an Aromatic
Amine Connected by an Amido Bond to
a Linker, in Google Patents. 2015
[50]Gawali SL, Barick KC, Shetake NG,
Rajan V, Pandey BN, Kumar NN, et al.
pH-labile magnetic nanocarriers for
intracellular drug delivery to tumor
cells. ACS Omega. 2019;4:11728-11736
[51]Ghosh AK, Brindisi M. Organic
carbamates in drug design and
medicinal chemistry. Journal of
Medicinal Chemistry. 2015;58:
2895-2940
[52] Kölmel DK, Kool ET. Oximes and
hydrazones in bioconjugation:
Mechanism and catalysis. Chemical
Reviews. 2017;117:10358-10376
[53] Fancui M, Quanxin W,
Zhuangzhuang Q, Yan Y. Micelles
prepared with cinnamaldehyde and
vancomycin by Schiff base reaction.
International Journal of New
Technology and Research. 2018;4
[54] Xiao N, Liang H, Lu J. Degradable
and biocompatible aldehyde-
functionalized glycopolymer conjugated
with doxorubicin via acid-labile Schiff
base linkage for pH-triggered drug
release. Soft Matter. 2011;7:
10834-10840
[55] Bhakay A, Rahman M, Dave RN,
Bilgili EJP. Bioavailability enhancement
of poorly water-soluble drugs via
nanocomposites: Formulation–
processing aspects and challenges. 2018;
10:86
[56] Benedetto Tiz D, Kikelj D, Zidar N.
Overcoming problems of poor drug
penetration into bacteria: Challenges
and strategies for medicinal chemists.
Expert Opinion on Drug Discovery.
2018;13:497-507
[57] Lock LL, LaComb M, Schwarz K,
Cheetham AG, Lin Y-A, Zhang P, et al.
Self-assembly of natural and synthetic
drug amphiphiles into discrete
supramolecular nanostructures. Faraday
Discussions. 2013;166:285-301
[58]Omolo CA, Kalhapure RS,
Jadhav M, Rambharose S, Mocktar C,
Ndesendo VM, et al. Pegylated oleic
acid: A promising amphiphilic polymer
for nano-antibiotic delivery. 2017;112:
96-108
[59] Su H, Zhang P, Cheetham AG,
Koo JM, Lin R, Masood A, et al.
Supramolecular crafting of self-
assembling camptothecin prodrugs with
enhanced efficacy against primary
cancer cells. Theranostics. 2016;6:1065
[60]Ma X, Bai S, Zhang X, Ma X, Jia D,
Shi X, et al. Enhanced tumor
penetration and chemotherapy
efficiency by covalent self-assembled
nanomicelle responsive to tumor
microenvironment. Biomacromolecules.
2019;20:2637-2648
[61]Wang Y, Cheetham AG,
Angacian G, Su H, Xie L, Cui H.
25
Nano/Microparticles Encapsulation Via Covalent Drug Conjugation
DOI: http://dx.doi.org/10.5772/intechopen.93364
Peptide–drug conjugates as effective
prodrug strategies for targeted delivery.
Advanced Drug Delivery Reviews. 2017;
110:112-126
[62] Lu Y, Lin J, Wang L, Zhang L, Cai C.
Self-assembly of copolymer micelles:
Higher-level assembly for constructing
hierarchical structure. Chemical
Reviews. 2020
[63] Cheetham AG, Zhang P, Lin YA,
Lock LL, Cui H. Supramolecular
nanostructures formed by anticancer
drug assembly. Journal of the American
Chemical Society. 2013;135:2907-2910
[64] Amitay Y, Shmeeda H, Patil Y,
Gorin J, Tzemach D, Mak L, et al.
Pharmacologic studies of a prodrug of
mitomycin C in pegylated liposomes
(Promitil®): High stability in plasma
and rapid thiolytic prodrug activation in
tissues. Pharmaceutical Research. 2016;
33:686-700
[65] Karaman R. Prodrugs design based
on inter- and intramolecular chemical
processes. Chemical Biology & Drug
Design. 2013;82:643-668
[66] Scicluna MC, Vella-Zarb L.
Evolution of nanocarrier drug-delivery
systems and recent advancements in
covalent organic framework–drug
systems. ACS Applied Nano Materials.
2020;3:3097-3115
[67] Taresco V, Alexander C, Singh N,
Pearce AK. Stimuli-responsive prodrug
chemistries for drug delivery. Advanced
Therapeutics. 2018;1:1800030
[68] Tian L, Yang Y, Wysocki LM,
Arnold AC, Hu A, Ravichandran B, et al.
Selective esterase–ester pair for targeting
small molecules with cellular specificity.
Proceedings of the National Academy of
Sciences. 2012;109:4756-4761
[69]Ding C, Li Z. A review of drug
release mechanisms from nanocarrier
systems. Materials Science and
Engineering: C. 2017;76:1440-1453
[70]Wang Z, Deng X, Ding J, Zhou W,
Zheng X, Tang G. Mechanisms of drug
release in pH-sensitive micelles for
tumour targeted drug delivery system:
A review. International Journal of
Pharmaceutics. 2018;535:253-260
[71]Dillon KM, Powell CR, Matson JB.
Self-immolative prodrugs: Effective
tools for the controlled release of sulfur
signaling species. Synlett. 2019;30:
525-531
[72]Meng X, Gao M, Deng J, Lu D,
Fan A, Ding D, et al. Self-immolative
micellar drug delivery: The linker
matters. Nano Research. 2018;11:
6177-6189
[73] Augustijns P, Annaert P, Heylen P,
Van den Mooter G, Kinget R. Drug
absorption studies of prodrug esters
using the Caco-2 model: Evaluation of
ester hydrolysis and transepithelial
transport. International Journal of
Pharmaceutics. 1998;166:45-53
[74] Amsberry KL, Gerstenberger AE,
Borchardt RT. Amine prodrugs which
utilize hydroxy amide lactonization. II.
A potential esterase-sensitive amide
prodrug. Pharmaceutical Research.
1991;8:455-461
[75]Meinig JM, Ferrara SJ, Banerji T,
Banerji T, Sanford-Crane HS,
Bourdette D, et al. Targeting fatty-acid
amide hydrolase with prodrugs for
CNS-selective therapy. ACS Chemical
Neuroscience. 2017;8:2468-2476
[76] Kraut J. Serine proteases: Structure
and mechanism of catalysis. Annual
Review of Biochemistry. 1977;46:
331-358
[77]Otto HH, Schirmeister T. Cysteine
proteases and their inhibitors. Chemical
Reviews. 1997;97:133-172
[78]Häse C, Finkelstein RA. Bacterial
extracellular zinc-containing
metalloproteases. Microbiology and
26
Nano- and Micro-Encapsulation - Techniques and Applications
Molecular Biology Reviews. 1993;57:
823-837
[79]Martin MT, Angeles TS,
Sugasawara R, Aman NI, Napper AD,
Darsley MJ, et al. Antibody-catalyzed
hydrolysis of an unsubstituted amide.
Journal of the American Chemical
Society. 1994;116:6508-6512
[80]Dai X, De Mesmaeker A, Joyce GF.
Cleavage of an amide bond by a
ribozyme. Science. 1995;267:237-240
[81] Kalia J, Raines RT. Hydrolytic
stability of hydrazones and oximes.
Angewandte Chemie (International Ed.
in English). 2008;47:7523-7526
[82] Ross PL, Wolfe JL. Physical and
chemical stability of antibody drug
conjugates: Current status. Journal of
Pharmaceutical Sciences. 2016;105:
391-397
[83] Fontaine SD, Reid R, Robinson L,
Ashley GW, Santi DV. Long-term
stabilization of Maleimide–Thiol
conjugates. Bioconjugate Chemistry.
2015;26:145-152
[84] Senevirathne SA, Washington KE,
Biewer MC, Stefan MC. PEG based anti-
cancer drug conjugated prodrug
micelles for the delivery of anti-cancer
agents. Journal of Materials
Chemistry B. 2016;4:360-370
[85] Lee E, Kim H, Lee I-H, Jon S. In vivo
antitumor effects of chitosan-
conjugated docetaxel after oral
administration. Journal of Controlled
Release. 2009;140:79-85
[86]Duncan R, Vicent MJ. Do HPMA
copolymer conjugates have a future as
clinically useful nanomedicines? A
critical overview of current status and
future opportunities. Advanced Drug
Delivery Reviews. 2010;62:272-282
[87] Jung B, Jeong Y-C, Min J-H, Kim J-
E, Song Y-J, Park J-K, et al. Tumor-
binding prodrug micelles of polymer–
drug conjugates for anticancer therapy
in HeLa cells. Journal of Materials
Chemistry. 2012;22:9385-9394
[88] Konkle BA, Stasyshyn O,
Chowdary P, Bevan DH, Mant T,
Shima M, et al. Pegylated, full-length,
recombinant factor VIII for prophylactic
and on-demand treatment of severe
hemophilia A. Blood, The Journal of the
American Society of Hematology. 2015;
126:1078-1085
[89] Coyle T, Reding MT, Lin J,
Michaels L, Shah A, Powell J. Phase I
study of BAY 94-9027, a PEG ylated B-
domain-deleted recombinant factor VIII
with an extended half-life, in subjects
with hemophilia A. Journal of
Thrombosis and Haemostasis. 2014;12:
488-496
[90]Devarajan PV, Dawre SM, Dutta R.
Infectious diseases: Need for targeted
drug delivery. In: Targeted Drug
Delivery: Concepts and Design.
Springer; 2015. pp. 113-148
[91] Van Driessche A, Kocere A,
Everaert H, Nuhn L, Van Herck S,
Griffiths G, et al. pH-sensitive
hydrazone-linked doxorubicin nanogels
via polymeric-activated Ester scaffolds:
Synthesis, assembly, and in vitro and
in vivo evaluation in tumor-bearing
zebrafish. Chemistry of Materials. 2018;
30:8587-8596
[92] Cao X, Le C, Lim K, Thi H, Kim G,
Gal Y. Redox-responsive core cross-
linked prodrug micelles prepared by
click chemistry for pH-triggered
doxorubicin delivery. Express Polymer
Letters. 2017;11:832-845
[93] Kamaly N, Xiao Z, Valencia PM,
Radovic-Moreno AF, Farokhzad OC.
Targeted polymeric therapeutic
nanoparticles: Design, development and
clinical translation. Chemical Society
Reviews. 2012;41:2971-3010
27
Nano/Microparticles Encapsulation Via Covalent Drug Conjugation
DOI: http://dx.doi.org/10.5772/intechopen.93364
[94]Modarresi-Saryazdi SM, Haddadi-
Asl V, Salami-Kalajahi M. N, N'-
methylenebis (acrylamide)-crosslinked
poly (acrylic acid) particles as
doxorubicin carriers: A comparison
between release behavior of physically
loaded drug and conjugated drug via
acid-labile hydrazone linkage. Journal of
Biomedical Materials Research Part A.
2018;106:342-348
[95] Rao KSVK, Zhong Q, Bielski ER,
da Rocha SRP. Nanoparticles of
pH-responsive, PEG–doxorubicin
conjugates: Interaction with an
in vitro model of lung adenocarcinoma
and their direct formulation in
propellant-based portable inhalers.
Molecular Pharmaceutics. 2017;14:
3866-3878
[96]Dong C, Zhou Q, Xiang J, Liu F,
Zhou Z, Shen Y. Self-assembly of
oxidation-responsive polyethylene
glycol-paclitaxel prodrug for cancer
chemotherapy. Journal of Controlled
Release. 2020;321:529-539
[97] Stirland DL, Nichols JW, Miura S,
Bae YH. Mind the gap: A survey of how
cancer drug carriers are susceptible to
the gap between research and practice.
Journal of Controlled Release. 2013;172:
1045-1064
[98] Sun Q, Zhou Z, Qiu N, Shen Y.
Rational design of cancer nanomedicine:
Nanoproperty integration and
synchronization. Advanced Materials.
2017;29:1606628
[99] Chakroun RW, Wang F, Lin R,
Wang Y, Su H, Pompa D, et al. Fine-
tuning the linear release rate of
paclitaxel-bearing supramolecular
filament hydrogels through molecular
engineering. ACS Nano. 2019;13:
7780-7790
[100]Mura S, Nicolas J, Couvreur P.
Stimuli-responsive nanocarriers for
drug delivery. Nature Materials. 2013;
12:991-1003
[101] Zhou Z, Ma X, Murphy CJ, Jin E,
Sun Q, Shen Y, et al. Molecularly precise
dendrimer–drug conjugates with
tunable drug release for cancer therapy.
Angewandte Chemie International
Edition. 2014;53:10949-10955
[102] Zhou Q, Shao S, Wang J, Xu C,
Xiang J, Piao Y, et al. Enzyme-
activatable polymer–drug conjugate
augments tumour penetration and
treatment efficacy. Nature
Nanotechnology. 2019;14:799-809
[103] Bhattacharyya J, Bellucci JJ,
Weitzhandler I, McDaniel JR,
Spasojevic I, Li X, et al. A paclitaxel-
loaded recombinant polypeptide
nanoparticle outperforms Abraxane in
multiple murine cancer models. Nature
Communications. 2015;6:1-12
[104]Wang J, Sun X, Mao W, Sun W,
Tang J, Sui M, et al. Tumor redox
heterogeneity-responsive prodrug
nanocapsules for cancer chemotherapy.
Advanced Materials. 2013;25:3670-3676
[105]Wang J, Hu S, Mao W, Xiang J,
Zhou Z, Liu X, et al. Assemblies of
peptide-Cytotoxin conjugates for
tumor-homing chemotherapy.
Advanced Functional Materials. 2019;
29:1807446
[106] Shen Y, Jin E, Zhang B, Murphy CJ,
Sui M, Zhao J, et al. Prodrugs forming
high drug loading multifunctional
nanocapsules for intracellular cancer
drug delivery. Journal of the American
Chemical Society. 2010;132:4259-4265
[107] Li J, Hu Z-E, Yang X-L, Wu W-X,
Xing X, Gu B, et al. GSH/pH dual-
responsive biodegradable camptothecin
polymeric prodrugs combined with
doxorubicin for synergistic anticancer
efficiency. Biomaterials Science. 2019;7:
3277-3286
[108] Tang J, Zeng Z, Yan J, Chen C,
Liu J, Feng X. Quantitative and high
28
Nano- and Micro-Encapsulation - Techniques and Applications
drug loading of self-assembled prodrug
with defined molecular structures for
effective cancer therapy. Journal of
Controlled Release. 2019;307:90-97
[109]Danial M, Telwatte S, Tyssen D,
Cosson S, Tachedjian G, Moad G, et al.
Combination anti-HIV therapy via
tandem release of prodrugs from
macromolecular carriers. Polymer
Chemistry. 2016;7:7477-7487
[110]Danial M, Andersen AH, Zuwala K,
Cosson S, Riber CF, Smith AA, et al.
Triple activity of lamivudine releasing
sulfonated polymers against HIV-1.
Molecular Pharmaceutics. 2016;13:
2397-2410
[111] Shibata A, McMullen E, Pham A,
Belshan M, Sanford B, Zhou Y, et al.
Polymeric nanoparticles containing
combination antiretroviral drugs for
HIV type 1 treatment. AIDS Research
and Human Retroviruses. 2013;29:
746-754
[112] Jiang Y, Cao S, Bright DK,
Bever AM, Blakney AK, Suydam IT,
et al. Nanoparticle-based ARV drug
combinations for synergistic inhibition
of cell-free and cell–cell HIV
transmission. Molecular Pharmaceutics.
2015;12:4363-4374
[113]Xiao Y, Liu J, Guo M, Zhou H, Jin J,
Liu J, et al. Synergistic combination
chemotherapy using carrier-free
celastrol and doxorubicin nanocrystals
for overcoming drug resistance.
Nanoscale. 2018;10:12639-12649
[114] Zhao C-Y, Cheng R, Yang Z,
Tian Z-M. Nanotechnology for cancer
therapy based on chemotherapy.
Molecules. 2018;23:826
[115] Ibrahim A, Twizeyimana E, Lu N,
Ke W, Mukerabigwi JF, Mohammed F,
et al. Reduction-responsive polymer
prodrug micelles with enhanced
endosomal escape capability for
efficient intracellular translocation and
drug release. ACS Applied Bio Materials.
2019;2:5099-5109
[116] Lu D, Wen X, Liang J, Gu Z,
Zhang X, Fan Y. A pH-sensitive nano
drug delivery system derived from
pullulan/doxorubicin conjugate. Journal
of Biomedical Materials Research Part B:
Applied Biomaterials: An Official
Journal of The Society for Biomaterials,
The Japanese Society for Biomaterials,
and The Australian Society for
Biomaterials and the Korean Society for
Biomaterials. 2009;89:177-183
[117] Yoo HS, Lee KH, Oh JE, Park TG.
In vitro and in vivo anti-tumor activities
of nanoparticles based on doxorubicin–
PLGA conjugates. Journal of Controlled
Release. 2000;68:419-431
[118] Shuai X, Ai H, Nasongkla N, Kim S,
Gao J. Micellar carriers based on block
copolymers of poly (ε-caprolactone)
and poly (ethylene glycol) for
doxorubicin delivery. Journal of
Controlled Release. 2004;98:415-426
[119]Ma L, Lin X, Li C, Xu Z, Chan C-Y,
Tse M-K, et al. A cancer cell-selective
and low-toxic bifunctional
heterodinuclear Pt(IV)–Ru(II)
anticancer prodrug. Inorganic
Chemistry. 2018;57:2917-2924
[120] Larson N, Ghandehari H. Polymeric
conjugates for drug delivery. Chemistry
of Materials. 2012;24:840-853
[121]Du J-Z, Du X-J, Mao C-Q, Wang J.
Tailor-made dual pH-sensitive
polymer–doxorubicin nanoparticles for
efficient anticancer drug delivery.
Journal of the American Chemical
Society. 2011;133:17560-17563
[122] Cai K, He X, Song Z, Yin Q,
Zhang Y, Uckun FM, et al. Dimeric drug
polymeric nanoparticles with
exceptionally high drug loading and
quantitative loading efficiency. Journal
of the American Chemical Society. 2015;
137:3458-3461
29
Nano/Microparticles Encapsulation Via Covalent Drug Conjugation
DOI: http://dx.doi.org/10.5772/intechopen.93364
[123] Su L, Li R, Khan S, Clanton R,
Zhang F, Lin Y-N, et al. Chemical design
of both a glutathione-sensitive dimeric
drug guest and a glucose-derived
nanocarrier host to achieve enhanced
osteosarcoma lung metastatic anticancer
selectivity. Journal of the American
Chemical Society. 2018;140:1438-1446
[124]Miller K, Erez R, Segal E, Shabat D,
Satchi-Fainaro R. Targeting bone
metastases with a bispecific anticancer
and antiangiogenic polymer–
alendronate–taxane conjugate.
Angewandte Chemie International
Edition. 2009;48:2949-2954
[125]Duncan R. Polymer conjugates as
anticancer nanomedicines. Nature
Reviews Cancer. 2006;6:688-701
[126] Cheetham AG, Chakroun RW,
MaW, Cui H. Self-assembling prodrugs.
Chemical Society Reviews. 2017;46:
6638-6663
[127] Yokoyama M, Miyauchi M,
Yamada N, Okano T, Sakurai Y,
Kataoka K, et al. Characterization and
anticancer activity of the micelle-forming
polymeric anticancer drug adriamycin-
conjugated poly (ethylene glycol)-poly
(aspartic acid) block copolymer. Cancer
Research. 1990;50:1693-1700
[128] Yokoyama M, Okano T, Sakurai Y,
Kataoka K. Improved synthesis of
adriamycin-conjugated poly (ethylene
oxide)-poly (aspartic acid) block
copolymer and formation of unimodal
micellar structure with controlled
amount of physically entrapped
adriamycin. Journal of Controlled
Release. 1994;32:269-277
[129] Kwon GS, Yokoyama M, Okano T,
Sakurai Y, Kataoka K. Biodistribution of
micelle-forming polymer–drug
conjugates. Pharmaceutical Research.
1993;10:970-974
[130] Kwon G, Suwa S, Yokoyama M,
Okano T, Sakurai Y, Kataoka K.
Enhanced tumor accumulation and
prolonged circulation times of micelle-
forming poly (ethylene oxide-aspartate)
block copolymer-adriamycin
conjugates. Journal of Controlled
Release. 1994;29:17-23
[131] Croy S, Kwon G. Polymeric
micelles for drug delivery. Current
Pharmaceutical Design. 2006;12:
4669-4684
[132] Ahmad Z, Shah A, Siddiq M,
Kraatz H. Polymeric micelles as drug
delivery vehicles. RSC Advances. 2014;
4:17028-17038. Go to original source
[133] Pattni BS, Chupin VV,
Torchilin VP. New developments in
liposomal drug delivery. Chemical
Reviews. 2015;115:10938-10966
[134]Medina SH, El-Sayed ME.
Dendrimers as carriers for delivery of
chemotherapeutic agents. Chemical
Reviews. 2009;109:3141-3157
[135] Torchilin V. Tumor delivery of
macromolecular drugs based on the EPR
effect. Advanced Drug Delivery
Reviews. 2011;63:131-135
[136] Paz-Ares L, Ross H, O’brien M,
Riviere A, Gatzemeier U, Von Pawel J,
et al. Phase III trial comparing paclitaxel
poliglumex vs docetaxel in the second-
line treatment of non-small-cell lung
cancer. British Journal of Cancer. 2008;
98:1608-1613
[137]Chitkara D, Mittal A, Behrman SW,
Kumar N, Mahato RI. Self-assembling,
amphiphilic polymer–gemcitabine
conjugate shows enhanced antitumor
efficacy against human pancreatic
adenocarcinoma. Bioconjugate
Chemistry. 2013;24:1161-1173
[138] Ishiguro S, Cai S, Uppalapati D,
Turner K, Zhang T, Forrest WC, et al.
Intratracheal administration of
hyaluronan-cisplatin conjugate
nanoparticles significantly attenuates
lung cancer growth in mice.
Pharmaceutical Research. 2016;33:
2517-2529
30
Nano- and Micro-Encapsulation - Techniques and Applications
[139] Tsuchiya K, Uchida T,
Kobayashi M, Maeda H, Konno T,
Yamanaka H. Tumor-targeted
chemotherapy with SMANCS in lipiodol
for renal cell carcinoma: Longer survival
with larger size tumors. Urology. 2000;
55:495-500
[140]Wang W, Li C, Zhang J, Dong A,
Kong D. Tailor-made gemcitabine
prodrug nanoparticles from well-
defined drug–polymer amphiphiles
prepared by controlled living radical
polymerization for cancer
chemotherapy. Journal of Materials
Chemistry B. 2014;2:1891-1901
[141] Chen X, Chen X, Chen W, Ma X,
Huang J, Chen R. Extended
peginterferon alfa-2a (Pegasys) therapy
in Chinese patients with HBeAg-
negative chronic hepatitis B. Journal of
Medical Virology. 2014;86:1705-1713
[142] Trapani A, Di Gioia S, Ditaranto N,
Cioffi N, Goycoolea FM, Carbone A,
et al. Systemic heparin delivery by the
pulmonary route using chitosan and
glycol chitosan nanoparticles.
International Journal of Pharmaceutics.
2013;447:115-123
[143]Mastria EM, Chen M, McDaniel JR,
Li X, Hyun J, Dewhirst MW, et al.
Doxorubicin-conjugated polypeptide
nanoparticles inhibit metastasis in two
murine models of carcinoma. Journal of
Controlled Release. 2015;208:52-58
[144] Zhong Q, Bielski ER, Rodrigues LS,
Brown MR, Reineke JJ, da Rocha SR.
Conjugation to poly (amidoamine)
dendrimers and pulmonary delivery
reduce cardiac accumulation and
enhance antitumor activity of
doxorubicin in lungmetastasis. Molecular
Pharmaceutics. 2016;13:2363-2375
[145] Eskow Jaunarajs KL, Standaert DG,
Viegas TX, Bentley MD, Fang Z,
Dizman B, et al. Rotigotine
polyoxazoline conjugate SER-214
provides robust and sustained
antiparkinsonian benefit. Movement
Disorders. 2013;28:1675-1682
[146] Park JH, Kwon S, Lee M, Chung H,
Kim J-H, Kim Y-S, et al. Self-assembled
nanoparticles based on glycol chitosan
bearing hydrophobic moieties as carriers
for doxorubicin: in vivo biodistribution
and anti-tumor activity. Biomaterials.
2006;27:119-126
[147]Murata M, Yonamine T, Tanaka S,
Tahara K, Tozuka Y, Takeuchi H. Surface
modification of liposomes using polymer-
wheat germ agglutinin conjugates to
improve the absorption of peptide drugs
by pulmonary administration. Journal of
Pharmaceutical Sciences. 2013;102:
1281-1289
[148] Ernsting MJ, Tang W-L,
MacCallum NW, Li S-D. Preclinical
pharmacokinetic, biodistribution, and
anti-cancer efficacy studies of a
docetaxel-carboxymethylcellulose
nanoparticle in mouse models.
Biomaterials. 2012;33:1445-1454
[149]Wang H, Wei J, Yang C, Zhao H,
Li D, Yin Z, et al. The inhibition of
tumor growth and metastasis by self-
assembled nanofibers of taxol.
Biomaterials. 2012;33:5848-5853
[150] Yang C, Bian M, Yang Z. A polymer
additive boosts the anti-cancer efficacy of
supramolecular nanofibers of taxol.
Biomaterials Science. 2014;2:651-654
[151]Ueno T, Endo K, Hori K, Ozaki N,
Tsuji A, Kondo S, et al. Assessment of
antitumor activity and acute peripheral
neuropathy of 1, 2-diaminocyclohexane
platinum (II)-incorporating micelles
(NC-4016). International Journal of
Nanomedicine. 2014;9:3005
[152] Katsumi H, Takashima M, Sano J-I,
Nishiyama K, Kitamura N, Sakane T,
et al. Development of polyethylene
glycol-conjugated alendronate, a novel
nitrogen-containing bisphosphonate
derivative: Evaluation of absorption,
safety, and effects after intrapulmonary
administration in rats. Journal of
Pharmaceutical Sciences. 2011;100:
3783-3792
31
Nano/Microparticles Encapsulation Via Covalent Drug Conjugation
DOI: http://dx.doi.org/10.5772/intechopen.93364
